Trust as strategy: How pharma wins by industrializing accountability
The pharmaceutical industry stands at a decisive moment. The EU AI Act's August 2026 compliance deadline for high-risk AI systems is not merely a regulatory hurdle - it is a strategic inflection point that will redefine the competitive landscape for BioPharma. Most organizations frame this as a compliance burden. The market leaders are already recognizing it as a strategic opportunity: the chance to build a scalable trust stack (governance, assurance, adoption) that accelerates the molecule-to-market journey and builds a defensive moat around their data assets.





